In addition, isorhapontigenin reduces vimentin protein levels by increasing METTL14 expression and up-regulating METTL14 mRNA by activating the transcription factor, FOXO3a, thereby impacting on BC progression (Zhang et al., 2021). Here, METTL14 is linked to breast cancer.